List of Excipients in Branded Drug HEPSERA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	HEPSERA	adefovir dipivoxil	61958-0501	CROSCARMELLOSE SODIUM
Gilead Sciences Inc	HEPSERA	adefovir dipivoxil	61958-0501	LACTOSE MONOHYDRATE
Gilead Sciences Inc	HEPSERA	adefovir dipivoxil	61958-0501	MAGNESIUM STEARATE
Gilead Sciences Inc	HEPSERA	adefovir dipivoxil	61958-0501	STARCH, CORN

# HEPSERA Excipient Strategy and Commercial Opportunities for Adefovir Dipivoxil

Last updated: August 15, 2026

HEPSERA is the branded 10 mg immediate-release tablet containing adefovir dipivoxil, an oral nucleotide analogue approved by the FDA for chronic hepatitis B. Its excipient system is conventional, low-cost, and suitable for generic replication. The main commercial opportunities are generic manufacture, excipient substitution, supply-chain qualification, regional licensing, and reformulation for markets where chronic hepatitis B remains undertreated.

Adefovir dipivoxil has limited commercial momentum in the United States because tenofovir-based therapies and newer nucleos(t)ide analogues have stronger market positions. The opportunity is greater in price-sensitive markets where adefovir remains listed in treatment guidelines, available through public tenders, or used when resistance or tolerability considerations affect drug selection.

What excipients are used in HEPSERA tablets?

HEPSERA uses a standard compressed-tablet formulation with a film coat. The FDA prescribing information identifies the following inactive ingredients:

Formulation component	Excipient	Primary function
Core	Croscarmellose sodium	Superdisintegrant; accelerates tablet breakup
Core	Lactose monohydrate	Diluent and filler
Core	Magnesium stearate	Lubricant
Core	Microcrystalline cellulose	Filler, dry binder, compression aid
Core	Pregelatinized starch	Binder and disintegrant
Core	Talc	Processing aid and anti-adherent
Film coat	Hypromellose	Film-forming polymer
Film coat	Titanium dioxide	Opacifier and colorant
Film coat	Triacetin	Plasticizer

The formulation is designed for immediate release rather than modified delivery. The excipients support mechanical strength, rapid disintegration, coating uniformity, and manufacturability at a relatively low drug load of 10 mg per tablet. [1]

Why does the HEPSERA excipient system matter?

Adefovir dipivoxil is a prodrug that is converted in vivo to adefovir. The commercial formulation does not depend on a sophisticated delivery platform, lipid carrier, enteric coating, or sustained-release matrix. That reduces formulation complexity and lowers the technical barrier to generic development.

The principal development risks are formulation equivalence, impurity control, dissolution performance, stability, and control of hydrolytic degradation. Excipient selection affects each of these parameters:

• Lactose and starch influence tablet porosity and water uptake.
• Croscarmellose sodium controls disintegration and can alter dissolution if used at different grades or concentrations.
• Magnesium stearate can slow wetting and dissolution when over-lubrication occurs.
• Talc affects powder flow and sticking during compression.
• Hypromellose and triacetin affect coating flexibility, appearance, and moisture protection.
• Titanium dioxide contributes to opacity but has limited therapeutic relevance.

The original excipient combination is therefore commercially reproducible, but generic manufacturers must establish that substitutions do not change dissolution, degradation, tablet hardness, or bioequivalence.

What is the FDA regulatory status of HEPSERA?

HEPSERA received FDA approval in 2002 under NDA 021449 for treatment of chronic hepatitis B in adults with evidence of active viral replication and either persistent elevations in serum aminotransferases or histologically active disease. The active ingredient is adefovir dipivoxil, a small-molecule antiviral. [2]

The regulatory profile has several commercial implications:

Regulatory issue	Commercial implication
Small-molecule tablet	Eligible for an abbreviated new drug application pathway
10 mg strength	Narrow product target for generic replication
Immediate-release dosage form	No complex delivery technology required
Chronic hepatitis B indication	Long-duration treatment and recurring demand
Renal toxicity warning	Requires labeling, pharmacovigilance, and renal-monitoring controls
No biologic structure	Biosimilar pathway does not apply
Older approval	Original FDA regulatory exclusivity is no longer the principal barrier

Adefovir is associated with dose-dependent nephrotoxicity, particularly at higher doses used historically in HIV treatment. The approved hepatitis B dose is 10 mg daily, but renal monitoring remains clinically relevant. [1] This safety profile limits opportunities to position adefovir as a broad replacement for tenofovir or entecavir.

When did HEPSERA lose regulatory exclusivity?

HEPSERA’s FDA approval occurred in 2002. The standard five-year new chemical entity exclusivity period and any initial pediatric exclusivity period are long expired. Generic competition is therefore principally governed by patents, FDA approval requirements, commercial demand, and local market rules rather than original regulatory exclusivity.

For a small-molecule product of this age, the principal diligence items are:

1. Current Orange Book patent listings for NDA 021449.
2. Any unexpired formulation, process, or method-of-use patents.
3. FDA-approved generic products and their marketing status.
4. State substitution rules and local registration requirements.
5. National treatment guidelines and procurement policies.

The Orange Book is the controlling FDA source for listed patents and therapeutic-equivalence information. [3] Because patent listings and product marketing status can change by edition, commercial decisions should rely on the applicable current Orange Book record rather than historical patent summaries.

What formulation patents protect HEPSERA?

The commercial formulation appears technically simple, and the original product does not rely on an obvious high-value delivery platform. Any historical patent protection would be more likely to concern the active compound, prodrug chemistry, pharmaceutical compositions, manufacturing processes, or therapeutic use than a complex excipient architecture.

For generic developers, the practical patent questions are:

Patent category	Relevance to adefovir dipivoxil
Active-ingredient or prodrug patent	Could have delayed early generic entry
Salt, polymorph, or crystalline-form patent	Relevant if the protected solid form is used
Composition patent	Could cover excipient ratios or dosage forms
Process patent	Could affect manufacture of adefovir dipivoxil
Method-of-use patent	Could cover treatment of chronic hepatitis B
Packaging or stability patent	Usually lower-value unless linked to product stability

An excipient substitution strategy can reduce composition-patent exposure if the generic product uses a materially different formulation. It does not eliminate risk from patents covering the active ingredient, prodrug synthesis, crystalline form, or method of treatment.

What generic entry risks exist for HEPSERA?

The technical barrier to adefovir dipivoxil generic entry is moderate to low. The commercial barrier is more significant.

Technical risk

A generic applicant must show pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. The target product is a 10 mg immediate-release tablet. Development work would normally include:

• Assay and content uniformity.
• Dissolution across multiple pH conditions.
• Impurity and degradation profiling.
• Tablet hardness and friability.
• Stability under long-term and accelerated conditions.
• Comparative bioavailability.
• Evaluation of lactose, starch, disintegrant, lubricant, and coating substitutions.

The prodrug’s chemical stability and conversion to adefovir require particular attention. A formulation that improves dissolution but increases hydrolysis during storage may not provide a commercial advantage.

Legal risk

A Paragraph IV strategy would depend on the patent status listed for the reference product at the time of filing. A generic applicant could certify that listed patents are invalid, unenforceable, or not infringed. If the reference sponsor brought suit within the statutory period, FDA approval could be subject to a 30-month stay, subject to the applicable statutory rules and litigation outcomes. [4]

Because HEPSERA is an older product, the probability that historical core patents remain blocking is lower than for recently approved drugs. The relevant risk is less likely to be a new basic patent and more likely to involve a surviving formulation, process, or use patent in a particular jurisdiction.

How should a generic manufacturer design an excipient strategy?

A generic manufacturer has two practical options.

Option 1: Replicate the reference excipients

Using the known HEPSERA excipient system reduces formulation uncertainty. A reference-like composition can simplify development because the formulation is already associated with acceptable clinical performance.

The disadvantages are supply dependence, possible patent overlap, and exposure to variability in excipient grade. Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and pregelatinized starch are widely available, so supply risk is generally manageable. Magnesium stearate and coating materials should be controlled by grade, particle size, moisture, and functionality rather than by chemical identity alone.

Option 2: Use a differentiated excipient platform

A manufacturer could replace lactose with mannitol, dibasic calcium phosphate, or an alternative cellulose-based filler. Pregelatinized starch could be replaced with a different binder-disintegrant system. A film coat could use a commercially available hypromellose-based premix rather than the original coating formulation.

A differentiated formulation may create several advantages:

• Reduced dependence on a single excipient supplier.
• Lower risk of lactose-related labeling restrictions.
• Improved tablet robustness.
• Better compression at smaller tablet weight.
• More stable procurement costs.
• Potentially simpler registration in markets with local excipient preferences.

The principal limitation is the need to demonstrate equivalent performance. Excipient differentiation has commercial value only if it improves cost, quality, manufacturability, or regulatory positioning.

What commercial opportunities exist for HEPSERA excipients?

The strongest opportunities are in generic finished-dose supply rather than in premium excipient innovation.

Generic finished products

A low-cost 10 mg tablet can be competitive in countries where hepatitis B treatment programs use tender procurement. The product is most attractive where:

• Adefovir remains authorized or guideline-listed.
• Tenofovir or entecavir is less affordable.
• Local manufacturers receive registration or procurement preferences.
• Treatment programs buy multi-month supplies.
• Existing antiviral manufacturing capacity can be repurposed.

Contract manufacturing and licensing

Companies with tableting, coating, and analytical capabilities can offer regional licensing or contract manufacturing. The product’s conventional formulation makes technology transfer comparatively straightforward. The critical transfer package would include:

• API particle-size and solid-state specifications.
• Blend and lubrication parameters.
• Compression-force ranges.
• Coating weight gain and spray conditions.
• Dissolution methods.
• Stability-indicating analytical methods.
• Impurity limits.
• Packaging and moisture-control requirements.

Excipient supply

The volume opportunity for individual excipients is modest because the tablet contains only 10 mg of active ingredient and conventional excipient quantities. The larger value lies in supplying a qualified, validated excipient package to multiple generic manufacturers.

Potential supplier differentiation includes:

• Direct-compression microcrystalline cellulose.
• Low-moisture lactose grades.
• High-functionality croscarmellose sodium.
• Co-processed filler-binder systems.
• Ready-to-use hypromellose coating premixes.
• Excipient systems optimized for rapid dissolution.

How does HEPSERA compare with competing hepatitis B drugs?

Adefovir faces a structural disadvantage against newer or stronger first-line therapies.

Product	Active ingredient	Dosage form	Commercial position
HEPSERA	Adefovir dipivoxil	10 mg tablet	Older antiviral with renal safety limitations
Viread and generics	Tenofovir disoproxil fumarate	Tablet	Broad use, stronger resistance profile
Vemlidy	Tenofovir alafenamide	Tablet	Lower systemic tenofovir exposure; premium positioning
Baraclude and generics	Entecavir	Tablet	Established first-line hepatitis B therapy
Generic adefovir	Adefovir dipivoxil	Tablet	Price-driven, regionally dependent opportunity

Adefovir may retain use in selected patients and markets, but its long-term growth potential is constrained by clinical substitution. The commercial case depends on manufacturing cost and local demand rather than product differentiation.

What is the revenue exposure and market outlook?

Revenue exposure for an original HEPSERA franchise is likely lower than for leading tenofovir or entecavir products because of generic competition and treatment displacement. A generic manufacturer should model the opportunity through volume rather than premium pricing.

Key commercial variables are:

• Number of treated hepatitis B patients in the target country.
• Share of treatment protocols permitting adefovir.
• Tender price per 10 mg tablet.
• Local API cost.
• Registration and pharmacovigilance expense.
• Competition from tenofovir disoproxil fumarate.
• Availability of domestic manufacturers.
• Public-sector procurement cycles.

The best opportunity is a low-cost, quality-assured product in markets where adefovir remains commercially relevant. A high-cost reformulation or branded excipient platform is unlikely to generate sufficient return without a specific regulatory or clinical advantage.

Is there biosimilar risk for HEPSERA?

No. HEPSERA contains a small-molecule active ingredient, so biosimilar regulation does not apply. Competitive risk comes from chemically synthesized generic products, therapeutic substitution, and newer antiviral products.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are manageable but not zero. The principal operational risks are API quality, impurity control, dissolution consistency, and long-term stability. The intellectual-property review should cover the active prodrug, manufacturing route, solid-state characteristics, compositions, and uses.

Geographic risk varies:

• In the United States, FDA ANDA requirements and Orange Book analysis control entry.
• In the European Union, national and centralized regulatory pathways depend on the product’s authorization history and target countries.
• In emerging markets, local patent rules, data requirements, compulsory licensing provisions, and tender eligibility can materially change the opportunity.
• In countries with weak patent enforcement but strong quality requirements, manufacturing execution may matter more than patent strategy.

Key Takeaways

• HEPSERA is a conventional 10 mg immediate-release adefovir dipivoxil tablet.
• Its excipients are widely available and do not create a high technical barrier to generic development.
• The core formulation uses lactose, microcrystalline cellulose, croscarmellose sodium, pregelatinized starch, magnesium stearate, talc, hypromellose, titanium dioxide, and triacetin.
• Regulatory exclusivity has expired; current patent and Orange Book analysis remains jurisdiction- and date-specific.
• The main generic risks are bioequivalence, stability, impurity control, and any surviving listed patents.
• The strongest commercial opportunities are low-cost generic supply, regional licensing, contract manufacturing, and qualified excipient packages.
• Adefovir’s commercial ceiling is limited by tenofovir and entecavir competition and by renal safety considerations.
• Biosimilar risk does not apply because adefovir dipivoxil is a small molecule.

FAQs

Can lactose be removed from a generic HEPSERA formulation?

Yes. Lactose can potentially be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable diluent. The substitute must preserve dissolution, stability, compressibility, and bioequivalence.

Does HEPSERA require an enteric coating?

No. The marketed product is an immediate-release film-coated tablet. An enteric system would add manufacturing and regulatory complexity without an established product-performance rationale.

Is adefovir dipivoxil suitable for a fixed-dose combination?

It is technically suitable for combination-tablet development, but commercial viability depends on clinical justification, regulatory acceptance, compatibility, and market demand. Tenofovir-based combinations are generally more commercially established.

Which excipient is most likely to affect dissolution?

Magnesium stearate is a key process variable because excessive lubrication can reduce wetting. Croscarmellose sodium, starch, tablet porosity, and compression force also materially affect disintegration and dissolution.

Can HEPSERA be relaunched with a premium excipient platform?

A premium relaunch would require a measurable advantage, such as improved stability, reduced tablet burden, renal-risk positioning supported by clinical evidence, or access to a market where the reformulation solves a specific manufacturing or regulatory problem. A conventional excipient change alone is unlikely to support premium pricing.

References

1. U.S. Food and Drug Administration. (2012). Hepsera (adefovir dipivoxil) tablets, prescribing information.
2. U.S. Food and Drug Administration. (2002). FDA approves Hepsera for chronic hepatitis B.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certifications.
5. National Library of Medicine. (2024). DailyMed: Hepsera, adefovir dipivoxil tablet, film coated.